1. Home
  2. LRE vs PPCB Comparison

LRE vs PPCB Comparison

Compare LRE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

HOLD

Current Price

$1.30

Market Cap

20.5M

Sector

N/A

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.76

Market Cap

20.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LRE
PPCB
Founded
2001
2007
Country
Japan
Australia
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
20.4M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LRE
PPCB
Price
$1.30
$0.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.5K
266.9K
Earning Date
01-01-0001
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
32.27
N/A
EPS
0.43
N/A
Revenue
$130,601,512.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.73
52 Week High
$2.97
$145.46

Technical Indicators

Market Signals
Indicator
LRE
PPCB
Relative Strength Index (RSI) 51.21 N/A
Support Level $1.25 N/A
Resistance Level $1.29 N/A
Average True Range (ATR) 0.06 0.00
MACD 0.02 0.00
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
LRE
PPCB

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: